

Curriculum vitae



PERSONAL INFORMATION

- Name: PD Dr. med. Dirk Sibbing, FESC
- Address: Roggensteiner Allee 216a, 82223 Eichenau; Germany
- Family status: married, 3 children
- Date and place of birth: 16.05.1978 in Detmold (Germany)
- Religion: evangelic

SCHOOL

1984 – 1988 Primary School Schlangen
1988 – 1997 Christian-Dietrich-Grabbe-Gymnasium in Detmold

STUDY

1997 – 2003 Medicine, Philipps-University Marburg
2003 – 2004 Practical Year, Ludwig-Maximilian University (LMU) München

CAREER

2004 – 2012 Deutsches Herzzentrum München (Klinik an der TU München)
- Member of the ISAResearch Center, Director of Platelet Function Lab, Research on: Antiplatelet agents, Genetics of cardiovascular disease
2012 – Ludwig-Maximilians-Universität München, Department of Cardiology

MEMBERSHIPS

Deutsche Gesellschaft für Kardiologie (DGK), Member of AG19 (DGK), Thrombosis Working Group (ESC), Fellow of the ESC, ISTH, GTH

REVIEW ACTIVITIES

The Lancet, Circulation, Circulation: Cardiovascular Interventions, JACC, JACC: Interventions, EHJ, ATVB, JTH, T&H, Platelets

AWARDS

ESC Young Investigator Award, 2010
GTH Nachwuchsförderpreis Blutungskrankheiten, 2011

SELECTED PUBLICATIONS

1. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abcixi-mab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. Sibbing D, Bernlochner I, Schulz S, Massberg S, Schömig A, Mehilli J, Kastrati A. J Am Coll Cardiol. 2012 Jul 31;60(5):369-77.

2. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O'Dono-ghue ML, Bernlochner I, Contant CF, Guo J, Sabatine MS, Schömig A, Neumann FJ, Kastrati A, Wiviott SD, Sibbing D. *Am Heart J*. 2011 Sep;162(3):518-26.e5.
3. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A. *Eur Heart J*. 2011 Jul;32(13):1605-13.
4. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. Sibbing D, Steinhubl SR, Schulz S, Schömig A, Kastrati A. *J Am Coll Cardiol*. 2010 Jul 20;56(4):317-8.
5. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N, Braun S, Schulz S, Schömig A, Kastrati A. *Eur Heart J*. 2010 May;31(10):1205-11.
6. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. Sibbing D, Stegherr J, Braun S, Mehilli J, Schulz S, Seyfarth M, Kastrati A, von Beckerath N, Schömig A. *J Am Coll Cardiol*. 2010 Feb 9;55(6):558-65.
7. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A. *Circulation*. 2010 Feb 2;121(4):512-8.
8. Risk of combining PPIs with thienopyridines: fact or fiction? Sibbing D, Kastrati A. *Lancet*. 2009 Sep 19;374(9694):952-4.
9. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. *J Am Coll Cardiol*. 2009 Mar 10;53(10):849-56.
10. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. *Eur Heart J*. 2009 Apr;30(8):916-22.

Munich, 10.05.2013



PD Dr. med. Dirk Sibbing